Correction to: Phase Ib/II Study of Biweekly TAS‐102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsColorectal Cancer Treatments and Studies · Cancer Treatment and Pharmacology · Peptidase Inhibition and Analysis
This is a correction to: Hironaga Satake, Takeshi Kato, Koji Oba, Masahito Kotaka, Yoshinori Kagawa, Hisateru Yasui, Masato Nakamura, Takanori Watanabe, Toshihiko Matsumoto, Takayuki Kii, Tetsuji Terazawa, Akitaka Makiyama, Nao Takano, Mitsuru Yokota, Yoshihiro Okita, Koreatsu Matoba, Hiroko Hasegawa, Akihito Tsuji, Yoshito Komatsu, Takayuki Yoshino, Kentaro Yamazaki, Hideyuki Mishima, Eiji Oki, Naoki Nagata, Junichi Sakamoto, Phase Ib/II Study of Biweekly TAS‐102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study), The Oncologist, Volume 25, Issue 12, December 2020, Pages e1855–e1863, https://doi.org/10.1634/theoncologist.2020-0643
In the originally published version of the manuscript, there was an error in the table PATIENT CHARACTERISTICS. Under subheading Detailed Patient Characteristics, the table lists the “RAS status” as follows:
”Wild-type: 25 (56.8%)
Mutant: 19 (43.2%)”
However, the correct values should be transposed:
”Wild-type: 19 (43.2%)
Mutant: 25 (56.8%)”
The labels were reversed due to a transcription error. The mistake does not affect any other part of the paper. This error has been outlined only in this correction notice to preserve the version of record.